Some researchers have demonstrated higher rates of programmed cell death ligand 1 (PD-L1) expression in TNBC patients than in patients with other breast cancers [11,12,13] and better survival with treatments that target PD1/PD-L1 in TNBC [14]. Here, CD274 is linked to breast carcinoma.